Loading…
← CockpitCompetitor Analysis › NOVO-B.CO Novo Nordisk A/S Class BOpen in the cockpit ↗

Novo Nordisk A/S Class BNOVO-B.COCompetitor analysis, valuation and peers

Denmark · DKK·Health Care›Pharmaceuticals: Major

Danish pharmaceutical company and global leader in diabetes and obesity treatments, including GLP-1 drugs like Ozempic and Wegovy.

≈ Denmark's Eli Lilly.Momentum laggard 17
Mkt cap
$177B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$213M
20-day average traded
Fwd P/E
11.8×
forward earnings
ROIC−WACC
+31.2 pp
WACC 9.9%
Hurdle
-20 pp
Req g minus delivered
Official | Implied
AA / AA
agencies · bond market
Next earnings
77 days
3 Feb 2027
Close · DKKDKK 271.45
1D-1.5%
1W-0.5%
1M+3.9%
3M-9.8%
6M-6.1%
YTD-16.5%
1Y-14.8%
ATR %2.8%
52w lowhigh33.8% off high

What Novo Nordisk A/S does

Danish pharmaceutical company and global leader in diabetes and obesity treatments, including GLP-1 drugs like Ozempic and Wegovy.

Earns mostly from injectable GLP-1 medicines for diabetes and obesity, sold through pharmacies and health systems, so the business now depends heavily on one drug family. The Novo Nordisk Foundation, through Novo Holdings, controls the votes. It is spending heavily on manufacturing, including three plants taken over from Catalent in 2024.

In one line: Denmark's Eli Lilly..

Products and services

  • GLP-1 diabetes drugs (Ozempic, Rybelsus)
  • GLP-1 obesity drugs (Wegovy)
  • Insulin products
  • Rare disease/biopharm

Customers

  • Diabetes and obesity patients
  • Hospitals and physicians
  • Payers/health systems

Where it sits in the supply chain

  • Pharmaceuticals
  • Biopharmaceutical R&D & manufacturing
  • Diabetes/obesity care

What could go right

  • GLP-1 obesity drug demand growth
  • Manufacturing capacity scale-up

What could go wrong

  • GLP-1 competition (Eli Lilly, generics/compounders)
  • Patent cliff/pricing pressure

Moat: wide (IP / patents, scale, brand). Patent-protected GLP-1 franchise plus decades of diabetes-care manufacturing scale and physician trust.

Headquarters: Bagsvaerd, Denmark · Founded: 1923 · Employees: 68,794

Named competitors

Novo Nordisk A/S at a glance

Size Novo Nordisk A/S (NOVO-B.CO) is a Denmark Health Care company (Pharmaceuticals: Major) with a market value of $177B, the largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 271.45 on 18 Nov 2026.

Performance Over six months the shares fell 6.1%, against +17.5% for the median peer and +6.3% for the Denmark market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 5.7% over the last twelve months (peer median +6.1%); the operating margin is 48.3% (peer median 26.6%).

Valuation It trades at 11.8× forward earnings against a peer median of 17.6× (6th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -20 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 31.2 points above its cost of capital (9.9% WACC).

Credit Novo Nordisk A/S has 18 bonds outstanding ($16.9B), rated AA by the agencies and trading like AA at a weighted spread of 70 bp.

Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026Peer median 115NOVO-B.CO 94
Six months, rebased to 100: Novo Nordisk A/S against the median of its 20 peers (local-currency closes).

Novo Nordisk A/S financials

Reported figures in DKK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueDKK 334BDKK 309BDKK 290BDKK 232BDKK 177B
Revenue growth—+6%+25%+31%—
Gross profitDKK 274BDKK 248BDKK 243BDKK 193BDKK 146B
EBITDADKK 178BDKK 150BDKK 148BDKK 111BDKK 81.0B
Net incomeDKK 113BDKK 102BDKK 101BDKK 83.7BDKK 55.5B
Free cash flowDKK 70.4BDKK 59.0BDKK 73.8BDKK 83.1BDKK 66.7B
Capital expenditureDKK 82.4BDKK 90.1BDKK 51.3BDKK 38.9BDKK 14.8B
Total debtDKK 134BDKK 131BDKK 103BDKK 27.0BDKK 25.8B

Quarterly statements and history in the cockpit →

Novo Nordisk A/S competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%PFEVRTXBMYSANAZNNOVNGSKREGNMRKRO4519MRK4502603259ABBVBAYNGALDSUNPHARMA600276NOVO-B.CO6-month return →1-month return →
Up and to the right = strong over both horizons. Novo Nordisk A/S is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%+15%+20%20×40×PFEVRTXBMYSANAZNNOVNGSKREGNMRKRO4519MRK4502603259ABBVBAYNGALDSUNPHARMAJNJ600276NOVO-B.CORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Novo Nordisk A/S is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%PFEVRTXBMYSANAZNNOVNGSKREGNMRKRO4519MRK603259ABBVGALDSUNPHARMAJNJ600276NOVO-B.COGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Novo Nordisk A/S is the large dot.

Novo Nordisk A/S competitors and peer comparison

Head to head with its named competitors (NOVO-B.CO vs LLY vs SAN.PA vs AZN.L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%

How Novo Nordisk A/S compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Novo Nordisk A/S against its 20 peers (data as of 18 Nov 2026)
MeasureNOVO-B.COPeer medianRank in peer set
1-month return+3.9%+4.1%10th lowest of 21
6-month return-6.1%+17.5%3rd lowest of 21
Distance from 52-week high-33.8%-5.9%lowest of 21
Revenue growth (TTM)+5.7%+6.1%10th lowest of 21
Operating margin48.3%26.6%2nd highest of 21
Forward P/E11.8×17.6×6th cheapest of 21
Growth the price implies (Req g, 7 yrs)-0.5%3.7%5th least demanding of 20
Growth delivered (Del g)+19.5%+6.4%2nd highest of 20
Hurdle (Req g minus delivered)-20.0 pp-1.3 ppleast demanding of 20
ROIC minus cost of capital+31.2 pp+8.1 pp2nd highest of 21
EV / EBITDA7.3×15.2×2nd cheapest of 19
Net debt / EBITDA0.5×1.3×5th least indebted of 19
Bond spread70 bp68 bp8th widest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Novo Nordisk A/S NOVO-B.CODenmark$177B-6%+6%48%11.8×-0.5%+19.5%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
AstraZeneca AZN.LUnited Kingdom$278B-2%+5%23%17.6×14.4%+15.7%
Novartis NOVN.SWSwitzerland$285B+11%-4%30%17.5×1.6%-0.2%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Merck & MRKUnited States$340B+23%+5%18%16.4×8.3%+9.3%
Roche RO.SWSwitzerland$381B+21%-1%31%19.9×1.7%+1.1%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
WuXi AppTec 603259.SSChina$64.2B+40%+32%43%17.0×7.2%+22.3%
AbbVie ABBVUnited States$506B+35%+11%36%18.1×-0.1%+6.0%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Johnson & Johnson JNJUnited States$656B+20%+8%26%24.2×3.7%+2.7%
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%

Novo Nordisk A/S bonds and credit

Novo Nordisk A/S has 18 bonds outstanding with $16.9B face value. The agencies rate it AA; its bonds trade like AA. Weighted yield 3.89%, a spread of 70 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Novo Nordisk A/S's main competitors?
Named competitors: Eli Lilly (LLY), Sanofi (SAN.PA), AstraZeneca (AZN.L), Pfizer (PFE). The cockpit's measured peer set (industry) also includes Pfizer (PFE), Vertex Pharmaceuticals (VRTX), Bristol Myers Squibb (BMY), Sanofi (SAN.PA), AstraZeneca (AZN.L), Novartis (NOVN.SW).
Is Novo Nordisk A/S expensive compared with its peers?
On forward p/e it trades at 11.8× against a peer median of 17.6×, 6th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -20 pp: the price already allows for a slowdown.
How has Novo Nordisk A/S stock performed?
Over six months to 18 Nov 2026 the shares returned -6.1% against +17.5% for the median peer; over one year -14.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.